Butyrate: Bridging Bench to Bedside -- Bringing Hope for Better Diagnostic and Therapeutic Options for Peanut Allergies
ISEF · 2021 Biomedical and Health Sciences First Award
Overview
Background: Distinctive roles for T-lymphocyte:Bacteroides fragilis cross-talk occurs in dampening peanut allergic responses. Butyrate is key to B.fragilis regulation of immune homeostasis. Current peanut allergy diagnostics and therapeutics are unreliable and may induce allergic reactions. Safer ex-vivo, non-allergen based diagnostics and therapies are critically needed. Methods: T-cells, B-cells and mast cells plus Ara-h-2 peanut allergen(PA) comprised the allergic model. For clinical translation, T-cells from individuals with vs without a peanut allergy were used. Microbes included B.fragilis(WT vs D-PSA-B.frag). Angiopoetin-1(protective) and Angiopoetin-2(induces pulmonary capillary leakage) from pulmonary endothelial cells measured end-organ response. Multiple PA exposure (up to 14 days) created a long-term, persistent T-cell allergic model. Results: Repeated dosing of either WT B.fragilis or butyrate, but not D-PSA-B.frag, prevented long-term T-cell allergic responses(dampening IL-4). Repeat butyrate dosing induced a (protective)CD-3+:PD-1-high phenotype. Butyrate could not rescue T-cells after PA exposure. Within pulmonary endothelial cell: immune model, PA induced decreased Ang-1 and increased Ang-2, IL-4, IL-6 and histamine expression. Butyrate prevented this response. To assess potential diagnostic test, T-cells from allergic individuals exposed to PA demonstrated distinct profile (increased PD-1+(60% vs 91%) and IL-4). As a potential therapeutic agent, butyrate prevented an allergic T-cell response, and induced a distinctive CD-3:PD-1-high subpopulation phenotype(<5% vs ~20%). Conclusion: This lays the basis for safe ex-vivo peanut allergy diagnostic test. B. fragilis derived butyrate may prove an effective, long-term, therapeutic option for peanut allergies.
Awards (1)
- First Award of $5,000 $5,000
Competition history
- ISEF 2021
Resources
Related projects
ISEF · 2018
From EpiPens to EpiGenetics: Understanding the Mechanisms Behind the Microbiome’s Impact on Peanut Allergies
ISEF · 2019
Ending the EpiPen Epidemic: Creating an Intestinal Organoid to Understand the Immune Mechanisms Involved in a Peanut Allergy
ISEF · 2026
Modulating a Novel Neuroepithelial Circuit in Food Allergy to Repair Barrier Dysfunction With Larazotide Acetate and Neuregulin-1
ISEF · 2024
Investigating the Impact of Parasitic Worm-Induced Secretions on Anaphylaxis
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair